• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

Introduction to 2-2-(propane-1-sulfonyl)-1H-1,3-benzodiazol-1-yl-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one (CAS No. 886904-58-1)

2-2-(propane-1-sulfonyl)-1H-1,3-benzodiazol-1-yl-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one (CAS No. 886904-58-1) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a benzodiazole core and a tetrahydroquinoline moiety, both of which are known for their diverse biological activities. The presence of a propane-1-sulfonyl group further enhances its chemical and biological properties, making it a promising candidate for various therapeutic applications.

The synthesis of 2-2-(propane-1-sulfonyl)-1H-1,3-benzodiazol-1-yl-1-(1,2,3,4-tetrahydroquinolin-1-y l)ethan-1-one involves a multi-step process that requires precise control over reaction conditions to ensure the formation of the desired product. Recent advancements in synthetic methodologies have enabled chemists to optimize these reactions, leading to higher yields and improved purity. The compound's structure has been extensively characterized using various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and X-ray crystallography.

In terms of biological activity, 2-2-(propane-1-sulfonyl)-1H-1,3-benzodiazol-1-y l)ethan-1-one has shown promising results in several preclinical studies. One of the key areas of interest is its potential as an inhibitor of specific enzymes involved in signal transduction pathways. For instance, it has been reported to exhibit potent inhibitory activity against certain kinases, which are crucial targets in the development of anticancer drugs. Additionally, the compound has demonstrated anti-inflammatory properties, making it a potential candidate for the treatment of inflammatory diseases.

The pharmacological profile of 2-2-(propane-1-sulfonyl)-1H-1,3-benzodiazol -yl)ethan -one has been further explored through in vitro and in vivo studies. In cellular assays, it has been shown to effectively modulate the activity of specific receptors and ion channels, which are implicated in various physiological processes. These findings suggest that the compound may have therapeutic potential in treating conditions such as neurodegenerative disorders and cardiovascular diseases.

To better understand the mechanism of action of 2 -sulfonyl)-benzodiazol -yl)ethan -one, researchers have conducted detailed molecular modeling studies. These computational approaches have provided insights into the binding interactions between the compound and its target proteins. The results indicate that the unique structural features of the compound contribute to its high affinity and selectivity for specific protein targets.

In addition to its therapeutic potential, -sulfonyl)-benzodiazol -yl)ethan -one has also been studied for its pharmacokinetic properties. Preclinical data suggest that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) characteristics. These properties are essential for ensuring that the compound can be effectively delivered to the target site and maintain sufficient concentrations to exert its therapeutic effects.

The safety profile of -sulfonyl)-benzodiazol -yl)ethan -one has been evaluated through a series of toxicological studies. These studies have shown that the compound is well-tolerated at therapeutic doses and does not exhibit significant toxicity or adverse effects in animal models. However, further clinical trials are necessary to fully assess its safety and efficacy in human subjects.

In conclusion, -sulfonyl)-benzodiazol -yl)ethan -one (CAS No. 886904-58-1) represents a promising lead compound in the development of novel therapeutics. Its unique structural features and diverse biological activities make it an attractive candidate for further investigation. Ongoing research efforts aim to optimize its properties and explore its potential applications in various medical fields.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)